Want to see ANNX full AI Analyst Report?
Total Valuation
Annexon Biosciences has a market cap or net worth of $745.05M. The enterprise value is $963.14.
Market Cap$745.05M
Enterprise Value$963.14
Share Statistics
Annexon Biosciences has 189,579,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding189,579,130
Owned by Insiders6.14%
Owned by Institutions39.69%
Financial Efficiency
Annexon Biosciences’s return on equity (ROE) is -0.98 and return on invested capital (ROIC) is -90.99%.
Return on Equity (ROE)-0.98
Return on Assets (ROA)-0.74
Return on Invested Capital (ROIC)-90.99%
Return on Capital Employed (ROCE)-0.92
Revenue Per Employee0.00
Profits Per Employee-2.25M
Employee Count92
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Annexon Biosciences is ―. Annexon Biosciences’s PEG ratio is -0.11.
PE Ratio―
PS Ratio0.00
PB Ratio3.68
Price to Fair Value3.68
Price to FCF-4.18
Price to Operating Cash Flow-4.34
PEG Ratio-0.11
Income Statement
In the last 12 months, Annexon Biosciences had revenue of 0.00 and earned -206.69M in profits. Earnings per share was -1.34.
Revenue0.00
Gross Profit-3.69M
Operating Income-216.41M
Pretax Income-206.69M
Net Income-206.69M
EBITDA-204.04M
Earnings Per Share (EPS)-1.34
Cash Flow
In the last 12 months, operating cash flow was -193.03M and capital expenditures -185.00K, giving a free cash flow of -193.22M billion.
Operating Cash Flow-193.03M
Free Cash Flow-193.22M
Free Cash Flow per Share-1.02
Dividends & Yields
Annexon Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.48
52-Week Price Change45.80%
50-Day Moving Average5.12
200-Day Moving Average5.39
Relative Strength Index (RSI)35.45
Average Volume (3m)2.55M
Important Dates
Annexon Biosciences upcoming earnings date is Nov 16, 2026, After Close (Confirmed).
Last Earnings DateAug 12, 2026
Next Earnings DateNov 16, 2026
Ex-Dividend Date―
Financial Position
Annexon Biosciences as a current ratio of 5.68, with Debt / Equity ratio of 13.25%
Current Ratio5.68
Quick Ratio5.68
Debt to Market Cap0.00
Net Debt to EBITDA0.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Annexon Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Annexon Biosciences EV to EBITDA ratio is -3.15, with an EV/FCF ratio of -3.45.
EV to Sales0.00
EV to EBITDA-3.15
EV to Free Cash Flow-3.45
EV to Operating Cash Flow-3.45
Balance Sheet
Annexon Biosciences has $209.24M in cash and marketable securities with $24.65M in debt, giving a net cash position of $184.59M billion.
Cash & Marketable Securities$209.24M
Total Debt$24.65M
Net Cash$184.59M
Net Cash Per Share$0.97
Tangible Book Value Per Share$1.36
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Annexon Biosciences is $13.23, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$13.23
Price Target Upside156.92% Upside
Analyst ConsensusModerate Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast10.96%